Doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy significantly suppresses tumor volume in breast cancer xenograft modelsCombining graphene and light shows promise for breast cancer

International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group Published July 17, 2026 Study authors: Gao Hua-Wei, Li Zhi-Hong, Lu Yan, Fang Yi-Gong, Shen Fang-Fang, Song Ling-Wei, Yu Fang-Zhou PubMed ↗ DOI ↗ Editorial oversight: Dr. Julia Lee, PhD · Oncology, Genomics & Drug Development

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that CPT shows significant tumor suppression in preclinical models but requires more pharmacokinetic data before clinical use.

This meta-analysis evaluates the efficacy of doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared to photothermal therapy (PTT) alone in breast cancer xenograft models. The analysis synthesized data from 9 studies involving 46 animals in each treatment group.

The primary finding indicates a significantly greater suppression of relative tumor volume (RTV) in the CPT group compared to PTT alone, with an effect size of -2.20 (95% CI: -2.76 to -1.65, p < 0.0001). While the statistical significance is high and heterogeneity is low, the authors note that secondary outcomes such as survival, toxicity, biodistribution, and clearance were only supported by limited reporting.

Several limitations are noted, including mild small-study asymmetry in funnel plots and the inherent limitations of using preclinical xenograft models. Furthermore, data regarding long-term safety and pharmacokinetic profiles remain insufficient. These findings suggest potential for CPT in breast cancer treatment but emphasize that more standardized safety and pharmacokinetic data are required before clinical translation can be considered.

How this fits prior evidence

This meta-analysis addresses a gap in the understanding of novel delivery systems for breast cancer, such as graphene nanoplatforms. While prior coverage has focused on systemic treatments like tamoxifen for reducing recurrence risk or adding angiogenesis inhibitors to neoadjuvant chemotherapy to improve response rates, this study explores a localized chemo-photothermal approach. The finding of significant tumor volume reduction in xenograft models provides a preclinical basis for evaluating new delivery mechanisms beyond the established pharmacological interventions previously noted.

When treating breast cancer, doctors are always looking for ways to make chemotherapy more effective while minimizing damage. A recent look at animal studies suggests that adding a graphene nanoplatform to photothermal therapy (using light to create heat) could change how we approach shrinking tumors.

In these tests, researchers compared two methods: using heat alone and using a combination of heat with doxorubicin loaded onto a graphene platform. The results showed that the combined method significantly reduced tumor volume compared to just using heat. This suggests the graphene helps deliver the medication more effectively where it is needed most.

While these results are promising, there are important notes to keep in mind. These findings come from preclinical animal models rather than human patients. Additionally, data on long-term safety and how the body clears the treatment were limited. More research is needed to see how this combination works in humans before it can be used in a clinic.

What this means for you:

Combining graphene with heat therapy reduced tumor size more than heat alone in early animal studies.

Common questions

How does this treatment work for breast cancer?

This method uses a combination called chemo-photothermal therapy. It involves loading the drug doxorubicin onto a graphene nanoplatform and using light to create heat. In animal tests, this combined approach was found to shrink tumor volume significantly more than using photothermal therapy alone.

Is this treatment safe for humans?

The study was conducted on animal models, not people. While the results showed promise in shrinking tumors, there is limited reporting on long-term safety and how the body clears the drug. More research is needed to determine if it is safe and effective for human patients.

How much better was the combined treatment than heat alone?

The study of 9 different trials showed a significant reduction in tumor volume for the group receiving the graphene-based combination. The results were statistically significant, showing that adding the graphene platform helped suppress the growth of the tumors more effectively than using heat by itself.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedDec 2026

PMID42449201

View Original Abstract ↓

OBJECTIVE: To systematically evaluate the efficacy of doxorubicin (DOX)-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared with photothermal therapy (PTT) alone on relative tumor volume (RTV) in breast cancer xenograft models and to summarize reported secondary safety and translational endpoints. METHODS: PubMed, Embase, Web of Science, and Cochrane Library were searched for animal studies published from January 2010 to December 2025 investigating DOX-loaded graphene nanomaterial-mediated CPT in breast cancer xenograft tumors. Hedges' g was used as the effect size measure, and standardized mean differences (SMDs) were pooled using a random-effects model. Heterogeneity, publication bias, subgroup analyses, sensitivity analyses, and qualitatively reported secondary endpoints were assessed. RESULTS: Nine breast cancer xenograft studies were included, involving 46 animals in the CPT group and 46 in the PTT group. The pooled SMD was -2.20 (95% CI: -2.76 to -1.65, < 0.0001), with negligible heterogeneity (I2 = 0.0%). Subgroup analyses showed no statistically significant differences by cell line, graphene type, or publication period (all > 0.05). Leave-one-out sensitivity analyses yielded pooled SMDs from -2.09 to -2.37. Funnel plot inspection and Egger's test suggested mild small-study asymmetry, but Trim-and-Fill correction did not change the direction or significance of the result. Secondary endpoint extraction showed limited survival, toxicity, biodistribution, and clearance reporting, supporting short-term tolerability but not definitive clinical translation. CONCLUSION: DOX-loaded graphene nanoplatform CPT was associated with significantly greater suppression of RTV than PTT alone in breast cancer xenograft models. The evidence supports a robust preclinical antitumor association while highlighting the need for standardized survival, long-term toxicity, biodistribution, and elimination studies before clinical application.

Doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy significantly suppresses tumor volume in breast cancer xenograft modelsCombining graphene and light shows promise for breast cancer

How this fits prior evidence

Common questions

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy significantly suppresses tumor volume in breast cancer xenograft modelsCombining graphene and light shows promise for breast cancer

How this fits prior evidence

Common questions

More on Breast Cancer

Study Details

First-line immune checkpoint inhibitor combinations improve overall survival in extensive-stage small-cell lung cancer

Immune checkpoint inhibitors combined with chemotherapy improve small cell lung cancer survival

Clinical research that matters. Delivered to your inbox.

Related in Oncology

From Other Specialties